High expression of USP22 is linked to a poor immunosuppressive microenvironment, and the CpG-aggregated methylation analysis shows that the gene is significantly hypomethylated in tumor samples, which is highly associated with its known upregulation in cancer.<h4>Conclusion</h4>USP22 may have potential relevance in cancer, and the pathways associated with it could offer possible targets for therapeutic intervention. This evidence concerns the gene USP22 and neoplasm.